Ross Moat - Mar 21, 2022 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role: CHIEF COMMERCIAL OFFICER
Signature: /s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol: KNSA
Transactions as of: Mar 21, 2022
Transactions value $: -$13,615
Form type: 4
Date filed: 3/23/2022, 04:30 PM
Previous filing: Sep 7, 2021
Next filing: Apr 11, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KNSA	Class A Common Share	Options Exercise		+2.27K	+35.79%		8.61K	Mar 21, 2022	Direct	F1
transaction	KNSA	Class A Common Share	Tax liability	-$13.6K	-1.24K	-14.4%	$10.98	7.37K	Mar 21, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	-2.27K	-100%	$0.00^*	0	Mar 21, 2022	Class A Common Share	2.27K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2	The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2022; there was no expiration date for the RSUs.